A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Recruiting now Phase 1 NCT06476808
Run by Bristol-Myers Squibb · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
- Participants must have an unresectable/metastatic carcinoma.
🚫 You may not be able to join if…
- Participants must not have Leptomeningeal metastases.
- Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
- Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- Local Institution - 0045, Columbus, Ohio, United States
- Local Institution - 0046, Dallas, Texas, United States
- Local Institution - 0049, Houston, Texas, United States
- BC Cancer Vancouver, Vancouver, British Columbia, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
- Jewish General Hospital, Montreal, Quebec, Canada
- Local Institution - 0036, Bordeaux, Aquitaine, France
- Local Institution - 0031, Villejuif, Val-de-Marne, France
+ 5 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06476808.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.